Navigation Links
French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec

French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec -- CLERMONT-FERRAND, France, September 1, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Acquisitions, Mergers and Takeovers, New Products & Services Click to view news release full screen  

French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec


CLERMONT-FERRAND, France, September 1, 2010 /PRNewswire/ -- Laboratoires Thea, the leading independent ophthalmic group in Europe, completes its innovative product range with the announcement of the final acquisition of Mydriasert(R). Mydriasert(R), the 1st mydriatic ophthalmic insert, is indicated for dilated fundus examination (DFE) or cataract surgery, the most widely implemented surgical procedure. Regarding cataract surgery, the market represents close to 300 000 procedures in the UK and Ireland and 3 million in Europe each year.

"This acquisition represents a significant addition to our product range and is completely in line with our strategy to become a leading provider of ophthalmic products. Our goal is to meet the needs of ophthalmologists in all major therapeutic classes so that we can be their daily partners, whatever their type of practice, and notably in ocular surgery," according to Laboratoires Thea COO Jean-Frederic Chibret. The agreement with Carl Zeiss Meditec includes the acquisition of the production site of Mydriasert(R) located in La Rochelle, France along with relevant staff. Mydriasert(R) is already commercialized in five European countries. Thanks to this agreement, Carl Zeiss Meditec will continue to concentrate on its core activities. Laboratoires Thea will develop sales through their subsidiaries and distributors.

Mydriasert(R) provides a genuine alternative to the mydriatic eye drops that are commonly used for mydriasis.

Mydriasert(R) allows one to obtain an effective and stable mydriasis with just one simple medical act which helps to avoid repeat installations of different mydriatic eye drops either for surgical procedures or diagnostic purposes.

In comparison to traditional mydriatic eye drops, Mydriasert(R) allows for fewer nursing procedures, this in turn helps to free up nursing time, reduce the risk of human errors and allows healthcare staff to spend more time with their patients[1]. The insert contains neither preservatives nor solvents.

This device, shaped like an oblong tablet, is applied beneath the eyelid and disperses both phenylephrin hydrochlorid and tropicamide, whose mechanisms of action are synergistic. Indeed, the alpha-sympathomimetic activity of phenylephrin induces an increase in pupil diameter, while the anti-cholinergic activity of tropicamide prevents the iris from contracting.

Heading towards new technologies

The acquisition of this French technology offers Thea new research and development opportunities. The system is comprised of a sterile, bio-compatible and porous matrix containing the ingredients which are gradually released into the lower conjunctival sac of the eye. The clinical situations in which it may be interesting to control the quantities of active ingredients administered onto the ocular surface are indeed quite numerous.

About Laboratoires Thea

Laboratoires Thea is the leading independent ophthalmic group in Europe. Founded in 1994, the company is a family business built on the heritage of over 150 years experience of the Chibret Family in Ophthalmology.

Today, Laboratoires Thea is ranked 3rd in France, 6th in Europe and 7th worldwide in the field of Ophthalmology. The company is present in 65 countries, owns 11 subsidiaries in Europe and had a turnover of EUR 171 million in 2009.[2]



[1] Korobelnik JF, Tavera C, Renaud-Rougier MB, El Meski S, Colin J.; The Mydriasert insert: an alternative to eye drops for preangiographic mydriasis; Le Journal Francais d'Ophtalmologie 2004 Oct;27(8):897-902

[2] Media contact: Burson-Marsteller France Tel. +33-1-41-86-76-26 - Cell: +33-6-07-59-43-95

SOURCE Laboratoires Thea
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
2. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
3. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
4. ResMed Acquires Laboratoires Narval
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
7. U.S. Preventive Medicine Acquires Specialty Disease Management
8. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
9. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
10. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
11. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015  Allergan plc (NYSE: AGN ... it will hold its R&D Day on November 4, ... – to 1:00 p.m. PT). The company will also ... at 9:00 a.m. ET (6:00 a.m. PT). ... --> Logo - ...
(Date:10/8/2015)... CAMBRIDGE, Mass. , Oct. 8, 2015 /PRNewswire/ ... has awarded approximately $40 million to the Broad ... whole genome sequencing of 20,000 individuals, as well ... sequencing and metabolite profiling. Trans-Omics for ... an initial step toward a larger initiative, which ...
(Date:10/8/2015)... FRANCISCO , Oct. 8, 2015  Nektar Therapeutics ... the Company,s pain and oncology portfolio during an Investor ... - 3:30 p.m. Eastern Time in New ... carcinoma.  Details of the NKTR-214 Phase 1/2 clinical program ... CD122-biased immune-stimulatory cytokine designed to preferentially stimulate the production ...
Breaking Medicine Technology:
... (SIX: RO, ROG; OTCQX: RHHBY) announced today that the David ... be using the Roche LightCycler ® 480 System, a ... gene expression and genetic variation, in advanced cancer research. ... 480 System to support several key areas of research it ...
... 2011 /PRNewswire/ -- Royal Philips Electronics ... States availability of the Ingenia MRI system, the ... Previously available in Europe, Canada and Japan, the ... Food and Drug Administration. Driven by Philips commitment ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... The Bank of America 500 NASCAR Sprint Cup ... Saturday, October 10th, defending race winner, Kevin Harvick, will battle it out for the ... and all of the stars of the NASCAR Sprint Cup Series. As part ...
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, entitled Bold ... Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The announcement was ... a celebratory gala on October 1st. , Many of the features of the ...
(Date:10/9/2015)... ... October 09, 2015 , ... With the FCPX LUT Vibrance pack ... footage. A LUT is a Lookup Table that contains a mathematical formula for modifying ... the table. This pack comes with 60 vibrant CUBE LUT files. , ...
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... ... now offering a special promotion on Invisalign, the orthodontic system that uses clear, ... The aligners are almost invisible against the teeth, which allow patients to complete ...
(Date:10/9/2015)... ... 09, 2015 , ... Confidence Plus Insurance has just celebrated ... initiative that involves working with a series of local charities throughout the California ... Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). , GPEVE provides a ...
Breaking Medicine News(10 mins):
... , New Report Highlights Best and Worst State ... Va., Sept. 10 A new report by The Vision Council, ... for children entering school are inconsistent, impeding children,s ability to succeed ... visual processing of information, undetected vision problems can severely impact a ...
... largest network of Hispanic health advocates joins President Obama,s efforts to improve ... , WASHINGTON, Sept. 9 "There was a clear ... reform. We need to work together to get the job done and ... our history, it is essential that we do this to support America,s ...
... , Statement attributable to: J. James Rohack, M.D. President, ... that Medical Liability Reform is Needed , , ... is unacceptable. The AMA will continue to work for reform that makes ... opportunity this year to achieve meaningful health reform for America,s patients and ...
... Sept. 9 In commemoration of the first September 11 National ... Los Angeles will host three 2-hour volunteer orientations for 100+ youth and ... tour of the chapter,s new state of the art Emergency Operation Center, ... recent California wildfires. , , What: ...
... MECHANICSBURG, Pa., Sept. 9 Select Medical Holdings ... the launch of its initial public offering of 33,333,333 shares ... is expected to be between $11.00 and $13.00 ... of common shares by Select, and Goldman, Sachs & Co., ...
... 9 As the nation awaits President Obama,s address on ... Philanthropic Collaborative (TPC) sent today a letter to the President ... foundations in the field of health. , , ... the social and economic effectiveness of health-related philanthropic activities. ...
Cached Medicine News:
CDIs new improved Implant Stabilizer has super-soft elastic bands with lace trim....
Bras and Breast Support...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
Medicine Products: